Celularity Inc (CELU)

$1.76 -0.03 (-1.68%)
Market Cap 42.15M
Revenue (ttm) 54.22M
Net Income (ttm) -57.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -106.77%
Debt to Equity Ratio 4.78
Volume 66,300
Avg Vol 67,732
Day's Range N/A - N/A
Shares Out 23.95M
Stochastic %K 11%
Beta 0.77
Analysts Strong Buy
Price Target $16.00

Company Profile

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBankin. Its lead therapeutic programs include CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified pla...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 768 2170
Address:
170 Park Avenue, Florham Park, United States
Nosay
Nosay Jun. 20 at 6:39 PM
$CELU we get news like this in USA and where do we go? https://www.medscape.com/viewarticle/europe-recommends-stem-cell-therapy-blood-cancers-2025a1000gja
0 · Reply
Andy_mc
Andy_mc Jun. 20 at 2:04 PM
$CELU G'wan ya c*nt ya :D
0 · Reply
Nosay
Nosay Jun. 19 at 2:55 PM
$CELU still posting new jobs. https://recruiting.paylocity.com/Recruiting/Jobs/Details/3198741 Don’t think this is a failing company as it is currently valued. Check out VERV. Just sold to Eli Lilly for around a billion dollars. Less revenue per year than we had a much higher burn rate. They were in the gene editing space not stem cells. But just an interesting acquisition.
1 · Reply
singa_stock
singa_stock Jun. 18 at 12:27 PM
$CELU So frustrating to wait for any kinda news. Sigh. Probably another 6 weeks before they announce their numbers (they announced around July end 2024). I would live to hear more about AI collaborations, revenue pipelines, Bali update, 510k submissions etc. earlier though.
0 · Reply
SwingNow
SwingNow Jun. 16 at 8:20 PM
$CELU gonna spike tomorrow before market open
1 · Reply
mf3rs
mf3rs Jun. 16 at 6:34 PM
$CELU where's the volume
1 · Reply
GreatGP
GreatGP Jun. 12 at 2:48 PM
$CELU don't fall in love here this is a trainwreck...interesting science but we're investors not scientist doctors or patients, only hope is T/O
1 · Reply
Coux
Coux Jun. 12 at 9:58 AM
$CELU I’m thinking (hopefully ) q1 report is finally finished and they fired beers after completing it, maybe they release it today, and q2 and pr on juli 31
0 · Reply
CharlieMungersghost
CharlieMungersghost Jun. 11 at 8:12 PM
$CELU that wouldn't be good. Hopefully the debt holders are forcing this improvement.
0 · Reply
singa_stock
singa_stock Jun. 11 at 6:45 PM
$CELU Just die already you fuckin POS stock.. Hariri should be ashamed.. there has been no meaningful PR to help retailers.
1 · Reply
Latest News on CELU
Celularity Announces Chief Financial Officer Transition

Jun 10, 2025, 4:15 PM EDT - 11 days ago

Celularity Announces Chief Financial Officer Transition

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Jun 2, 2025, 8:00 AM EDT - 19 days ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Celularity Receives Nasdaq Notice Regarding Form 10-Q

May 30, 2025, 5:30 PM EDT - 22 days ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Celularity Announces Full Year 2024 Operating and Financial Results

May 9, 2025, 9:15 AM EDT - 6 weeks ago

Celularity Announces Full Year 2024 Operating and Financial Results

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 25, 2025, 5:30 PM EDT - 2 months ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Apr 14, 2025, 8:00 AM EDT - 2 months ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 25, 2025, 8:00 AM EST - 4 months ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Feb 24, 2025, 8:00 AM EST - 4 months ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 10, 2024, 8:00 AM EST - 6 months ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Dec 6, 2024, 8:00 AM EST - 7 months ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 27, 2024, 5:00 PM EST - 7 months ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Nov 20, 2024, 8:30 AM EST - 7 months ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 23, 2024, 8:30 AM EDT - 8 months ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 18, 2024, 6:00 PM EDT - 8 months ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Oct 16, 2024, 5:15 PM EDT - 8 months ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 5, 2024, 4:05 PM EDT - 10 months ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 28, 2024, 4:45 PM EDT - 10 months ago

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Aug 23, 2024, 5:00 PM EDT - 10 months ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jul 31, 2024, 8:30 AM EDT - 11 months ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

May 14, 2024, 9:15 AM EDT - 1 year ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 19, 2024, 5:30 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Apr 8, 2024, 9:00 AM EDT - 1 year ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 26, 2024, 9:00 AM EDT - 1 year ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 20, 2024, 9:15 AM EDT - 1 year ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 14, 2024, 9:15 AM EDT - 1 year ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 12, 2024, 9:20 AM EDT - 1 year ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Mar 7, 2024, 9:35 AM EST - 1 year ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Celularity Announces 1-for-10 Reverse Stock Split

Feb 23, 2024, 4:10 PM EST - 1 year ago

Celularity Announces 1-for-10 Reverse Stock Split

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 14, 2024, 4:05 PM EST - 1 year ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Feb 1, 2024, 9:00 AM EST - 1 year ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 25, 2024, 9:00 AM EST - 1 year ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Celularity Releases CEO Letter to Shareholders

Jan 18, 2024, 1:40 PM EST - 1 year ago

Celularity Releases CEO Letter to Shareholders

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 4, 2024, 1:00 PM EST - 1 year ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Jan 3, 2024, 12:00 PM EST - 1 year ago

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Oct 18, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Sep 7, 2023, 4:10 PM EDT - 1 year ago

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Aug 29, 2023, 9:00 AM EDT - 1 year ago

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Celularity Inc. Announces $3 Million Registered Direct Offering

Jul 27, 2023, 9:07 AM EDT - 2 years ago

Celularity Inc. Announces $3 Million Registered Direct Offering

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Jul 27, 2023, 9:00 AM EDT - 2 years ago

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Jul 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Jun 29, 2023, 4:05 PM EDT - 2 years ago

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Jun 1, 2023, 9:15 AM EDT - 2 years ago

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

May 23, 2023, 10:56 AM EDT - 2 years ago

CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity's Halal-Certified Biomaterial Products

May 23, 2023, 8:10 AM EDT - 2 years ago

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity's Halal-Certified Biomaterial Products

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn's Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

May 19, 2023, 4:21 PM EDT - 2 years ago

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn's Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

Nosay
Nosay Jun. 20 at 6:39 PM
$CELU we get news like this in USA and where do we go? https://www.medscape.com/viewarticle/europe-recommends-stem-cell-therapy-blood-cancers-2025a1000gja
0 · Reply
Andy_mc
Andy_mc Jun. 20 at 2:04 PM
$CELU G'wan ya c*nt ya :D
0 · Reply
Nosay
Nosay Jun. 19 at 2:55 PM
$CELU still posting new jobs. https://recruiting.paylocity.com/Recruiting/Jobs/Details/3198741 Don’t think this is a failing company as it is currently valued. Check out VERV. Just sold to Eli Lilly for around a billion dollars. Less revenue per year than we had a much higher burn rate. They were in the gene editing space not stem cells. But just an interesting acquisition.
1 · Reply
singa_stock
singa_stock Jun. 18 at 12:27 PM
$CELU So frustrating to wait for any kinda news. Sigh. Probably another 6 weeks before they announce their numbers (they announced around July end 2024). I would live to hear more about AI collaborations, revenue pipelines, Bali update, 510k submissions etc. earlier though.
0 · Reply
SwingNow
SwingNow Jun. 16 at 8:20 PM
$CELU gonna spike tomorrow before market open
1 · Reply
mf3rs
mf3rs Jun. 16 at 6:34 PM
$CELU where's the volume
1 · Reply
GreatGP
GreatGP Jun. 12 at 2:48 PM
$CELU don't fall in love here this is a trainwreck...interesting science but we're investors not scientist doctors or patients, only hope is T/O
1 · Reply
Coux
Coux Jun. 12 at 9:58 AM
$CELU I’m thinking (hopefully ) q1 report is finally finished and they fired beers after completing it, maybe they release it today, and q2 and pr on juli 31
0 · Reply
CharlieMungersghost
CharlieMungersghost Jun. 11 at 8:12 PM
$CELU that wouldn't be good. Hopefully the debt holders are forcing this improvement.
0 · Reply
singa_stock
singa_stock Jun. 11 at 6:45 PM
$CELU Just die already you fuckin POS stock.. Hariri should be ashamed.. there has been no meaningful PR to help retailers.
1 · Reply
CharlieMungersghost
CharlieMungersghost Jun. 11 at 5:44 PM
$CELU let's fill that gap and get on with this 10x
1 · Reply
mf3rs
mf3rs Jun. 11 at 5:12 PM
$CELU I sure hope we do not get the dreaded financials need to be restated pr next.
0 · Reply
elchulo58
elchulo58 Jun. 11 at 2:49 PM
$CELU I’m a bullish trader, but it going to go down. Based on the chart. Longs buy on dip. Swing and day traders sell.
1 · Reply
esb016
esb016 Jun. 10 at 10:31 PM
$CELU Dor a company this size constantly missing key filings is embarassing. Good riddance that the clown is gone. The other firm will atleast do a better job and no more steep drops in stock price. Plus they are now more serious about the business. With 54m in revenue and RFK, stock whould go up 8x from here. Holding 100k shares at $1.39
0 · Reply
singa_stock
singa_stock Jun. 10 at 8:39 PM
$CELU Beers just took 5% market cap with him along with investor trust. They better release some PR to make up for this shitty news. I do expect PR by July 31 (same as last year), but earlier the better. I am hoping they saved some good news just for such scenarios.
2 · Reply
CharlieMungersghost
CharlieMungersghost Jun. 10 at 8:35 PM
$CELU heads gotta roll! Reporting has been a joke.
0 · Reply
Nosay
Nosay Jun. 10 at 8:17 PM
$CELU beers terminated. I don’t see this as a bad thing at all.
2 · Reply
luckydog2
luckydog2 Jun. 10 at 8:17 PM
$CELU https://www.globenewswire.com/news-release/2025/06/10/3097149/0/en/Celularity-Announces-Chief-Financial-Officer-Transition.html
0 · Reply
FunCoupons00
FunCoupons00 Jun. 10 at 6:36 PM
$CELU wake me up at 10$
0 · Reply
singa_stock
singa_stock Jun. 9 at 11:17 PM
$CELU Either it is sheer luck or sheer planning but this company seems to have gotten aligned with RFK’s vision of where our health economy is going. Now we just need the management to be on top of their A game on execution and announce some FUCKIN kick ass news !!
0 · Reply
lyn30
lyn30 Jun. 6 at 3:26 PM
$CELU Bought again
0 · Reply
singa_stock
singa_stock Jun. 5 at 3:09 PM
$CELU Don’t agree with him on most things including this one, but any talk of stem cells gets more eyes here.. so 🤷‍♂️ https://www.nytimes.com/2025/06/05/health/kennedy-stem-cells-experimental-treatments.html
1 · Reply